Drug intelligence / Profile preview

olevaprubart

Development stage: Unknown
Lead developer: ImageneBio
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous, Intravenous

Overview

Olevaprubart (IMG-007) is a next-generation human monoclonal antibody targeting the OX40 receptor. Developed by ImageneBio (formerly Inmagene Biopharmaceuticals), it is designed to block the interaction between OX40 and its ligand (OX40L) on activated T cells, thereby modulating inflammatory responses. The antibody is Fc-engineered to silence antibody-dependent cellular cytotoxicity (ADCC), which prevents the depletion of T cells, and features an extended half-life of approximately five weeks. It is primarily being developed for the treatment of moderate-to-severe atopic dermatitis and alopecia areata.

Other names: olevaprubart

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)CD28 (Cluster of Differentiation 28)

Beyond the preview

Go deeper on olevaprubart.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on olevaprubart.

Explore the full profile